Fig 1: Osteoclast-secreted IL-19 primes IL20RB-expressing tumor cells for proliferation in bone.(A) Quantification of EdU+ A549 cells with IL20RB overexpression and/or treatment of CM from murine bone marrow–derived osteoclasts (OC) for 24 hours. Representative images are shown on the right. OC CM was mixed with A549 culture medium at a 1:3 ratio. (B) Quantification of EdU+ HBM1 cells with IL20RB knockdown and/or treatment with OC CM for 24 hours. (C–E) Organoid formation of A549 (C), HBM1 (D), and LLC (E) after treatment with OC CM. OC CM was mixed with organoid culture medium at a 1:3 ratio. (F and G) Organoid formation of A549 (F) and HBM1 (G) after treatment with OC CM and/or the IL-19–neutralizing antibody (10 µg/mL). (H) Organoid formation of LLC cells after treatment with recombinant IL-19 protein. (I and J) IL-19 secretion of osteoclasts after treatment with control F12K medium or CM from A549 (I) or HBM1 (J) with or without CSF2 knockdown. Scale bars: 100 µm. P values were obtained by 2-tailed unpaired t test. Data are represented as mean ± SD.
Supplier Page from Proteintech Group Inc for Human GM-CSF ELISA Kit